Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, the data showed results of a phase PDS’s candidate PDS0101 in combination with two immune-modulating agents on 25 patients.
Dr Lauren Wood, PDS’ chief medical officer, said: “The data provide early evidence of notable clinical activity, and we saw effective tumour regression in these patients"
The achievement of a 67% tumour reduction among all HPV16-positive cancer patients supports further clinical investigation of the Versamune platform's potential ability to induce high levels of tumour-specific CD8+ killer T-cells that attack cancer, she added.
"The interim data demonstrating that this response was limited only to patients with HVP16-positive cancer, and also the fact that all responding patients who have stayed on treatment continue to show ongoing responses after a median duration of 8 months solidifies our belief that PDS0101's ability to generate a robust, targeted T-cell response."
This might have the potential to significantly improve clinical outcomes for patients with advanced, refractory HPV16-associated cancers who have limited treatment options, Wood added.
Shares in NetScientific, which holds 5.75% of PDS, rose 33% to 199p, effectively meaning the shares have doubled in two days.
The share price had already rocketed yesterday on news yesterday from another portfolio company, Proaxis, which struck a licensing deal with AstraZeneca PLC (LON:AZN) over the validation and global commercialisation of an assay associated with coronavirus vaccines.